Treatment with beta-blockers and nebivolol in the light of new recommendations: conclusions from the 32nd Congress ESH Milan 2023
Authors:
Andrej Dukát 1; Ján Gajdošík 2; Ján Kyselovič 1
Authors‘ workplace:
V. interná klinika LF UK a UNB, Nemocnica Ružinov, Bratislava
1; Neštátna ambulancia pre dospelých v Nových Zámkoch
2
Published in:
Forum Diab 2024; 13(1): 27-29
Overview
Recent Congress of the European Society of Hypertension in June 2023 in Milan newly evaluated the position of betablockers for the therapy of arterial hypertension. Prof. G. Mancia’s team recommended, reflecting the new results from the clinical studies, this group of cardiovascular drugs again for certain indications in the first line of therapy also for the patients with arterial hypertension. In the clinical pharmacotherapy the main interest tis focused to nebivolol, as the most important drug from the betablockers of the third generation.
Keywords:
hypertension – betablockers – nebivolol
Sources
Unger T, Borghi C, Charchar F et al. 2020 International society of hypertension global hypertension practice guidelines. Hypertension 2020; 75(6): 1334–1367. Dostupné z DOI: <http://dx.doi.org/10.1161/HYPERTENSIONAHA.120.15026>.
Poirier L, Tobe SW. Contemporary Use of Beta-Blockers: Clinical Relevance of Subclassification. Canad J Cardiol 2014; 305 Suppl): S9-S15. Dostupné z DOI: <http://dx.doi.org/10.1016/j.cjca.2013.12.001>.
NICE. Hypertension in adults: diagnosis and management. NICE Guideline 136. NICE 2019. Dostupné z WWW: <https://www.nice.org.uk/guidance/ng136>.
Wiysonge CS, Bradley HA, Volmink J et al. Beta-blockers for hypertension. Cochrane Data-base Syst Rev 2012; 11: CD002003. Dostupné z DOI: <http://dx.doi.org/10.1002/14651858.CD002003.pub4>.
Messerli FH, Bangalore S. The blood pressure landscape: schism among guidelines, confusion among physicians, and anxiety among patients. J Am Coll Cardiol 2018; 72(11): 1313–1318. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2018.07.026>.
Messerli FH, Bangalore S, Mandrola JM. β blockers switched to first-line therapy in hypertension. Lancet 2023; 402(10414): 1802–1804. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(23)01733–6>.
Williams B, Mancia G, Spiering W et al. [ESC Scientific Document Group]. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J 2018; 39(33): 3021–3104. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehy339>.
Davies M, Aroda V, Collins B et al. Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2022; 45(11): 2753–2786. Dostupné z DOI: <http://dx.doi.org/10.2337/dci22–0034>.
Wei J, Galaviz KI, Kowalski AJ e al. Comparison of cardiovascular events among users of different classes of antihypertension medications: a systematic review and network meta-analysis. JAMA Netw Open 2020; 3(2): e1921618. Dostupné z DOI: <http://dx.doi.org/10.1001/jamanetworkopen.2019.21618>.
Mancia G, Kreutz R, Brunström M et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens; 41(12): 1874–2071. Dostupné z DOI: <http://dx.doi.org/10.1097/HJH. 000000000000–3480>.
Dukát A, Kriška M, Payer J. Postavenie betablokátorov tretej generácie a nebivololu v kardiovaskulárnej farmakoterapii. Int Med 2020; 20(2): 93–95.
Bangalore S, Messerli FH, Kostis JB et al. Cardiovascular protection using beta-blockers: a critical review of the evidence. J Am Coll Cardiol 2007; 50(7): 563–572. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2007.04.060>.
Arazi HC, Gonzales M. Nebivolol: Does the key lie in β3 agonism? Vascul Dis Ther 2017; 2(6):1–6. Dostupné z DOI: <http://dx.doi.org/10.15761/VDT.1000138>.
Howlett JG. Nebivolol: Vasodilator Properties and Evidence for Relevance in Treatment of Cardiovascular Disease. Can J Cardiol 2014; 305(5 Suppl): S29-S37. Dostupné z DOI: <http://dx.doi.org/10.1016/j.cjca.2014.03.003>.
Cheng JWM. Nebivolol: A Third-Generation Beta-Blocker for Hypertension. Clin Ther 2009; 31(3): 447–462. Dostupné z DOI: <http://dx.doi.org/10.1016/j.clinthera.2009.03.007>.
Fongemie J, Felix-Getzik E. A Review of Nebivolol Pharmacology and Clinical Evidence. Drugs 2015; 75(12): 1349–1371. Dostupné z DOI: <http://dx.doi.org/10.1007/s40265–015–0435–5>.
Labels
Diabetology Endocrinology Internal medicineArticle was published in
Forum Diabetologicum
2024 Issue 1
Most read in this issue
- Folistatin and type 2 diabetes mellitus
- Long term protective effects of empagliflozine in whole spectrum of patients with type 2 diabetes mellitus from early stages of disease
- Telemedicine in outpatient diabetes practice
- New recommendations for arterial hypertension management and blood pressure targets for type 2 diabetes mellitus